An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 88
- 试验地点
- 28
- 主要终点
- 18-Months' Overall Survival Percentage (PPS)
研究概览
简要总结
The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib post-nephrectomy vs Sunitinib post-nephrectomy patients.
详细描述
Patients, all planned for nephrectomy, will be stratified according to the Heng risk criteria (high risk patients vs. intermediate risk patients) and randomized in a 2:1 ratio to receive Intuvax (INN: ilixadencel)+ Sunitinib or Sunitinib alone.
Two doses of Intuvax (INN: ilixadencel) will be administered in to the primary tumour before nephrectomy. The control group will be scheduled for nephrectomy directly.
All patients will start Sunitinib treatment 5-8 weeks after operation.
Results from the phase I study, together with the results reported in the literature on the use of autologous dendritic cells (DCs) in combination with Sunitinib encourage Immunicum aktiebolag (AB) to further investigate the possibility of exploiting Intuvax (INN: ilixadencel) 10 million cells/dose when combined with Sunitinib for the treatment of mRCC patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly (<6 months) diagnosed RCC (histological/cytological verification is optional) with at least one (1) CT-verified metastasis ≥10mm for which complete metastasectomy is not planned. US patients must have verified clear-cell tumor histology
- •Planned resection of primary tumor
- •Primary tumor diameter ≥40 mm
- •Candidate for first-line therapy with sunitinib initiated 5-8 weeks after nephrectomy
- •Female or male ≥18 years of age
- •Willing and able to provide informed consent
- •Adequate hematological parameters, i.e:
- •B-Leukocyte count ≥4.5 x10e9/L
- •B-Platelet count ≥150 x10e9/L
- •B-Hemoglobin ≥90 g/L
- •S-creatinine and S-bilirubin ≤ 1.5 x upper limit of normal (ULN). Serum alanine aminotransferase (S-ALAT) and serum aspartate aminotransferase (S-ASAT) ≤ 2.5 x ULN (or ≤5 in case of liver metastases)
- •Female who has been post-menopausal for more than one (1) year or female of childbearing potential agreeing to use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner or combined birth control pills]) Female of childbearing potential must have a negative from Screening until 90 days after last dose of Intuvax and/or until completed sunitinib treatment whichever occurs later.blood pregnancy test at Screening, and if randomized to vaccination a negative blood or urine pregnancy test within one (1) day before each dose of Intuvax) and must not be lactating.
- •or Male agreeing to use condoms from Screening until 90 days after last dose of Intuvax and/or until completed sunitinib treatment whichever occurs later, or male having a female partner who is using a highly efficient method of contraception as described above.
排除标准
- •Life expectancy less than 4 months
- •Central nervous system (CNS) metastasis that is symptomatic or progressing or untreated or that required current therapy (e.g. evidence of new or enlarging CNS metastasis or new neurological symptoms attributable to CNS metastases)
- •Active autoimmune disease which requires treatment with systemic immunosuppressive agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus (SLE), vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases
- •Treatment with per oral systemic corticosteroids exceeding 10mg/day within seven (7) days before Screening until nephrectomy (inhaled, intranasal and local steroids accepted irrespective of dose)
- •Known cardiomyopathy and/or clinical significant abnormal ECG findings at Screening disqualifying the patient from nephrectomy and from subsequent sunitinib treatment
- •Karnofsky performance status <70%
- •National Cancer Institute (NCI) Common Terminology criteria for Adverse Events (CTCAE) Grade 3 hemorrhage within 28 days before Screening
- •Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
- •Clinically significant gastrointestinal abnormalities
- •Uncontrolled hypertension, or uncontrolled diabetes mellitus
- •Pulmonary embolism within 12 months before screening
- •Prior history of invasive cancer within 5 years before screening, except for adequately treated in situ carcinomas or non-melanoma skin cancer
- •Ongoing infection that requires parenteral treatment with antibiotics
- •Active or latent virus disease (HIV, hepatitis B and hepatitis C)
- •Eastern Cooperative Oncology Group (ECOG) performance status >2 after optimization of analgesics
- •Abnormal and clinical significant coagulation parameters at the discretion of the Investigator, i.e.:
- •Prothrombin Time - International Normalized Ratio (PT-INR)
- •Activated Partial Thromboplastin Time (APTT) patients being treated with anticoagulants are excluded if the coagulation parameters are outside the therapeutic intervals as described in the summary of product characteristics (SmPC) / United States prescribing information (USPI) for the administered treatment
- •Known major adverse reaction/event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)
- •Known hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study products
- •Prior systemic antitumour therapy within 28 days before Screening Visit. However, local radiation therapy to any area except for the abdominal/retroperitoneal area including the kidney tumour is allowed
- •Exposure to other investigational products within 28 days prior to Screening Visit
- •patients on anticoagulants for whom temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy at the discretion of the investigator and or per local standard of care) during vaccination and nephrectomy, is not an option
- •History of alcohol or substance abuse
- •Any reason that, in the opinion of the Investigator, contraindicates that the patient participates in the study
研究组 & 干预措施
Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib
Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
干预措施: Sunitinib (Drug)
Nephrectomy+Sunitinib
Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
干预措施: Sunitinib (Drug)
结局指标
主要结局
18-Months' Overall Survival Percentage (PPS)
时间窗: At 18 months (544 days)
The 18-month survival percentage was defined as the percentage of patients alive 18 months after randomization.
18-Months' Overall Survival Percentage (FAS)
时间窗: At 18 months (544 days)
The 18-month survival percentage was defined as the percentage of patients alive 18 months after randomization.
Overall Survival (OS) - Days (FAS)
时间窗: From the randomization to the date of death, up to 5 years after the last participant's 18-month survival data.
OS is the time from randomization until date of death. The patients who were alive at the end of study were followed for survival status (alive/date of death) through medical records, databases and public records according to the time frame below. Due to censored data, estimates of upper 95% CI could not be determined in all reporting groups.
Overall Survival - Days (PPS)
时间窗: From the randomization to the date of death, up to 5 years after the last patient's 18-month survival data.
OS is the time from randomization until date of death. The patients who were alive at the end of study were followed for survival status (alive/date of death) through medical records, databases and public records according to the time frame below. Due to censored data, upper 95% CI could not be determined in all reporting groups.
次要结局
- Progression Free Survival (PFS) From Start of Sunitinib According to RECIST 1.1.(From Sunitinib-Start to progressive disease or death, up to 18 months.)
- Objective Response Rate (ORR) From Start of Sunitinib Treatment and Duration of Response in Each Subgroup.(From start of sunitinib treatment up to 18 months)
- Number of Participants With Specific Best Overall Response(From start of sunitinib treatment up to 18 months)
- Disease Control Rate(From start of sunitinib treatment up to 18 months)
- Duration of Response(From first date of CR or PR until date of PD or death, up to 18 months.)
- Duration of Clinical Benefit(From first date of clinical benefit (CR, PR or SD) until date of PD or death, up to 18 months.)
- Duration of Stable Disease(From first date of SD until PD or date of death, up to 18 months.)
- Time to Progression (TTP)(Time from Sunitinib-Start to date of either PD according to RECIST 1.1 or clinical progression as evaluated by the Investigator, up to 18 months.)
- Percentage of Tumor Area With Infiltrating Cluster of Differentiation 8+ (CD8+) T-cells(At resection of primary tumor.)